Abstract
N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoid that inhibits growth and induces apoptosis in many human cell lines. We explored the effects of HPR on human T-cell lymphotropic virus type I (HTLV-I)-positive and HTLV-I-negative malignant T-cell lines, most of which are resistant to all-trans retinoic acid. Clinically achievable concentrations of HPR caused a dramatic inhibition of cell proliferation, G0/G1 arrest, and massive apoptosis in all tested malignant T cells, while no effect was observed on resting or activated normal lymphocytes. Interestingly, HTLV-I-negative cell lines were significantly more sensitive to HPR compared to HTLV-I-positive and Tax-transfected cells. In HTLV-I-negative cells only, HPR-induced apoptosis was associated with ceramide accumulation, sharp decrease in mitochondrial membrane potential, and activation of caspases 8, 9 and 3, and could be partially reverted by the caspase inhibitor z-VAD suggesting that Tax protects infected cells from ceramide accumulation and caspase-mediated apoptosis. In HTLV-I-positive cells, HPR treatment rapidly induced proteasomal-mediated degradation of p21, downregulated cyclin D1, and upregulated bax protein levels. These findings support a potential therapeutic role for HPR in both HTLV-I-associated adult T-cell leukemia/lymphoma (ATL) and HTLV-I-negative peripheral T-cell lymphomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
De Luca LM . Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 14: 2924–2933.
Lippman SM, Lotan R . Advances in the development of retinoids as chemopreventive agents. Symposium: diet, natural products and cancer prevention. J Nutr 2000; 130: 479S–482S.
Fontana JA, Rishi AK . Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002; 16: 463–472.
Warrell R, de Thé H, Wang Z, Degos L . Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189.
Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML et al. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood 2001; 98: 2862–2864.
Dawson MI, Zhang X, Hobbs PD, Jong L In: Livrea MA (ed). Vitamin A and Retinoids: an Update of Biological Aspects and Clinical Applications: Synthetic Retinoids and Their Usefulness in Biology and Medicine##Basel: Birkhauser, Verlag, 2000, pp. 161–196.
Delia D, Aiellom A, Lombardim L, Giuseppem P, Pelicci G, Grignani G et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036–6041.
Wu JM, DiPietrantonio AM, Hsieh TC . Mechanism of fenretinide (HPR)-induced cell death. Apoptosis 2001; 6: 377–388.
Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Moglia D et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11: 2036–2042.
De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002; 86: 24–27.
Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA et al. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002; 8: 2835–2842.
Bazarbachi A, Hermine O . Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res 2001; 78: 79–92.
Hermine OD, Bouscary A, Gessain A, Turlure P, Leblond V, Franck N et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749–1751.
Bazarbachi A, Hermine O . Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 1: 186–190.
Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A . A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3: 276–282.
Bazarbachi A, El-Sabban ME, Nasr R, Hermine O, de The H . Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278–283.
El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000; 96: 2849–2855.
Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F et al. Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-I infected leukemic cells. Blood 2003; 101: 4576–4582.
Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, Hermine O et al. Retinoic acid dramatically enhances the arsenic trioxide induced cell cycle arrest and apoptosis in retinoic acid receptor α-positive Human T cell leukemiavirus type-I transformed cells. Hematol J 2001; 2: 127–135.
Miyatake JI, Maeda Y . Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia. Leukemia 1997; 11: 401–407.
Chan LN, Zhang S, Shao J, Waikel R, Thompson EA, Chan TS . N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma 1997; 25: 271–280.
O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ . N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002; 5: 902–910.
Hatoum A, El-Sabban ME, Khoury J, Yuspa SH, Darwiche N . Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis 2001; 22: 1955–1963.
Bligh EG, Dyer WJ . A rapid method of total lipid extraction and purification. Can J Biochem Phys 1959; 37: 911–917.
Bielawska A, Perry DK, Hannun YA . Determination of ceramides and diglycerides by the diglyceride kinase assay. Anal Biochem 2001; 298: 141–150.
Zar JH . Biostatistical Analysis. 4th edn New Jersey: Prentice Hall, 1999.
Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE . Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis 2002; 3: 447–456.
Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. Blood 1995; 15: 359–367.
Sun SY, Yue P, Lotan R . Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 5: 403–410.
Asumendi A, Morales MC, Alvarez A, Arechaga J, Perez-Yarza G . Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl) retinamide-induced apoptosis. Br J Cancer 2002; 12: 1951–1956.
Weinberg WC, Denning MF . P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 2002; 13: 453–464.
Gartel AL, Tyner AL . The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639–649.
DiPietrantonio AM, Hsieh TC, Juan G, Traganos F, Darzynkiewicz Z, Wu JM . Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 2000; 15: 4331–4335.
Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z . N-(4-hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 2003; 3: 259–266.
DiPietrantonio AM, Hsieh TC, Olson SC, Wu J M . Altered expression of the G1/S checkpoint regulators (cyclin D1, cdk4, pRB) and transient modulation of poly(ADP-ribose) polymerase and ceramide level changes by fenretinide N-(4-hydroxyphenyl) retinamide, 4-HPR) in human promyelocytic HL-60 leukemic cells. Int J Cancer 1998; 78: 53–61.
Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP . Increase in ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 9: 1138–1146.
Sun SY, Yue P, Lotan R . Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403–410.
Jeang KT . Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 2001; 12: 207–217.
Cereseto A, Diella F, Mulloy JC, Cara A, Michieli P, Grassmann R et al. p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood 1996; 88: 1551–1560.
de La Fuente C, Santiago F, Chong SY, Deng L, Mayhood T, Fu P et al. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol 2000; 74: 7270–7283.
Kawata S, Ariumi Y, Shimotohno K . p21(Waf1/Cip1/Sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded tax. J Virol 2003; 77: 7291–7299.
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d' Etudes des Lymphomes de l' Adulte. Blood 1998; 92: 76–82.
Cheng AL, Su IJ, Chen CC, Tien HF . Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol 1994; 12: 1185–1192.
Toshima M, Nagai T, Izumi T, Tarumoto T, Imagawa S, Komatsu N et al. All-trans-retinoic acid treatment for chemotherapy-resistant acute adult T-cell leukemia. Int J Hematol 2000; 72: 343–345.
Acknowledgements
We are thankful to Dr Riad Sadek and Mr Ahmad Abou-Tayyoun for their help with the statistical analysis. This work was supported by grants from the Lebanese National Council for Scientific Research, the American University of Beirut University Research Board and Medical Practice Plan, the Diana Tamari Sabbagh Foundation, the CNRS, ARECA, HERN, the Programme Franco-Libanais ‘CEDRE’, and the Eli Lilly International Foundation.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Darwiche, N., Hatoum, A., Dbaibo, G. et al. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. Leukemia 18, 607–615 (2004). https://doi.org/10.1038/sj.leu.2403245
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403245
Keywords
This article is cited by
-
HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches
Apoptosis (2008)
-
Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax
Leukemia (2007)
-
Mechanisms of fenretinide-induced apoptosis
Apoptosis (2006)